Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;78(3):454-63.
doi: 10.1111/j.1747-0285.2011.01156.x. Epub 2011 Jul 14.

High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei

Affiliations

High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei

Zachary B Mackey et al. Chem Biol Drug Des. 2011 Sep.

Abstract

New drugs are needed to treat human African trypanosomiasis because the currently approved treatments are toxic or limited in efficacy. One strategy for developing new drugs involves discovering novel genes whose products can be targeted for modulation by small-molecule chemotherapeutic agents. The Trypanosoma brucei genome contains many genes with the potential to become such targets. Kinases represent one group of genes that regulate many important cell functions and can be modulated by small molecules, thus representing a promising group of enzymes to screen for potential therapeutic targets. RNAi screens could help identify the most promising kinase targets, but the lack of suitable assays represents a barrier for optimizing the use of this technology in T. brucei. Here, we describe an RNAi screen of a small RNAi library targeting 30 members of the T. brucei kinome utilizing a luciferase-based assay. This screen both validated the luciferase-based assay as a suitable method for conducting RNAi screens in T. brucei and also identified two kinases (CRK12 and ERK8) that are essential for normal proliferation by the parasite.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow of luciferase-based RNAi Screen
31 partial cDNA fragments were PCR amplified from genomic DNA and subcloned into RNAi plasmids. The plasmids were linearized with NotI and transfected into T. brucei 90-13 to make stable RNAi clones A). Each of the T. brucei RNAi clones was counted then diluted with HMI-9 and transferred to 96-well plates so that each well contained 104 clones. Each row contained 12 replicates of RNAi clones that were maintained in either control medium or induction medium containing 100 ng/mL tetracycline, allowing 4 RNAi clones to be tested per plate. At the appropriate time point (days 3, 6 or 9 post-induction), luciferase reagent was added to the plates and RLU values were obtained with read with a luminometer B).
Figure 2
Figure 2. Pair-wise comparison of RNAi clones
Mean RLU (RLUMean) values of control vs. tetracycline induced RNAi clones as graphed in histograms. Bars in the histogram represent the RLUMean from an entire row of RNAi clones. Each plate contains the data from 4 clones in which the control and tetracycline-induced RLUMean was evaluated in a pair-wise manner. Replicas were made from each plate prior to reading and then assayed on every third day for nine days, as represented by each column (Day 3, Day 6, Day 9). The mean and standard deviations were calculated for each row. The Student’s t- test was used to determine which RNAi clones had significant differences in the RLUMean in response to tetracycline induction. Clones in which the RLUMean values were significantly different are represented by the hatched bars.
Figure 3
Figure 3. Pair-wise counting of RNAi clones
The 5 RNAi clones that showed a significant change in growth rate over all 3 reads were each expanded into individual flasks and counted every day for 9 days. The numbers were plotted as a line graph with the log10 cell number plotted on the y-axis. For each clone, the closed diagrams (● ▲ ◆) represent the respective clones growing under control conditions whereas open diagrams (○ △ ◇) represent the cones being induced with tetracycline at 100 ng/ul. TbK5 and TbK24 represent the clones with strong growth phenotypes after RNAi induction A). TbK6, TbK8 and TbK16 represent the clones with subtle growth phenotypes after RNAi induction B). The values on the graph represent the averages of 3 separate experiments.
Figure 4
Figure 4. HTS assay format for RNAi library
Each of the wells tested were inoculated with 104 RNAi clones in medium containing 100 ng/µL tetracycline. Duplicated screens of the RNAi library were conducted on each 96-well plate. The data points graphed on the scatter plot represent the log-transformed RLU values for each of the replicated RNAi clones tested in the screen. A). The RLUMean values for all of the RNAi clones with SD were calculated and then graphed as a separate scatter plot B). The Zscore at 1.96 below the mean RLU depicted by the dashed line represents the cut-off point for the p =0.05.
Figure 5
Figure 5. Northern blot analysis of K5 and K24
The two proliferation-deficient clones identified from screening the 30 RNAi clones in HTS format were further analyzed by northern blot analysis. Total RNA was isolated from control or tetracycline-induced clones after 48 hours post induction. Labeled gene specific probes were hybridized to the blots and visualized by autoradiography. CRK12 A). ERK8 B).

References

    1. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21:402–408. - PubMed
    1. King CH, Bertino AM. Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Negl Trop Dis. 2008;2:e209. - PMC - PubMed
    1. Blum J, Burri C. Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Med Wkly. 2002;132:51–56. - PubMed
    1. Burchmore RJ, Ogbunude PO, Enanga B, Barrett MP. Chemotherapy of human African trypanosomiasis. Curr Pharm Des. 2002;8:256–267. - PubMed
    1. Nok AJ. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res. 2003;90:71–79. - PubMed

Publication types

Substances